Comerica Bank Has $7.23 Million Holdings in Hologic, Inc. $HOLX

Key Points

• Comerica Bank increased its stake in Hologic, Inc. by 9.8% in the first quarter, holding 117,098 shares valued at approximately $7.23 million.
• Hologic reported $1.08 earnings per share, exceeding estimates, alongside a 1.2% year-over-year revenue growth, amounting to $1.02 billion for the quarter.
• Analysts' ratings for Hologic depict a consensus of Moderate Buy with an average target price of $78.00, following upgrades from various investment firms.

Comerica Bank lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 9.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 117,098 shares of the medical equipment provider's stock after acquiring an additional 10,449 shares during the period. Comerica Bank owned approximately 0.05% of Hologic worth $7,233,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Farther Finance Advisors LLC lifted its stake in Hologic by 22.3% during the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after purchasing an additional 335 shares during the period. SG Americas Securities LLC lifted its position in shares of Hologic by 116.6% during the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after buying an additional 5,172 shares during the period. Brevan Howard Capital Management LP boosted its stake in Hologic by 85.5% in the 4th quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock valued at $1,401,000 after buying an additional 8,960 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock valued at $1,980,000 after acquiring an additional 528 shares during the period. Finally, Teachers Retirement System of The State of Kentucky raised its stake in Hologic by 4.5% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider's stock worth $1,108,000 after acquiring an additional 767 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Trading Down 0.8%

Hologic stock traded down $0.51 during mid-day trading on Tuesday, hitting $66.61. The stock had a trading volume of 916,744 shares, compared to its average volume of 1,620,470. The stock has a 50-day simple moving average of $66.24 and a two-hundred day simple moving average of $62.54. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $14.82 billion, a PE ratio of 27.64, a P/E/G ratio of 2.44 and a beta of 0.57. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company's quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Saturday. UBS Group lifted their target price on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. Argus raised Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price on the stock in a report on Monday, August 18th. Stephens dropped their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.